SEC Form 4 · accession 0000874015-19-000002
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stanley T Crooke
Officer — Chairman and CEO · Director
Period of report
Jan 2, 2019
Accepted (ET)
Jan 3, 2019 · 7:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $53.77 | Jan 2, 2019 | A | 143,400 | A | Jan 2, 2020 | Jan 1, 2026 | Common Stock | 143,400 | 143,400 | D |
| Employee Stock Option (right to buy)F1 | $53.77 | Jan 2, 2019 | A | 12,000 | A | Jan 2, 2020 | Jan 1, 2026 | Common Stock | 12,000 | 12,000 | I |
Explanation of responses
- F1Grant of 01/02/2019 to reporting person or reporting person's wife (as indicated) of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019.